The drugmaker looks expensive today, but the real story is what you are actually paying for the earnings of tomorrow.
At a glance, Merck (MRK) stock looks pricey. Trading at about 35.3 times the last twelve months of reported earnings, it carries the kind of premium that makes many investors stop looking. But that headline number is not the full story.
Look two years out, and the picture changes completely. On the earnings analysts expect by 2027, that same $128 share price is only about 13.2 times earnings. That is a 63% lower multiple, a steep discount that materializes as projected earnings grow into today's price. For a patient holder, this is the effective price you are paying for the business of 2027. It is crucial to note that part of this drop reflects a difference in accounting: the trailing multiple is based on reported GAAP earnings, while forward estimates typically use a non-GAAP basis that excludes certain charges.
The honest question is never the price tag itself, but whether the growth that creates this discount is likely to arrive. Here, the analyst consensus seems grounded. The forecast calls for revenue to grow about 3.3% a year. That is right in line with the 2.9% revenue growth the company actually delivered over the last twelve months and the 4.9% it posted in the most recent quarter. The projection does not require a heroic leap, just a continuation of current momentum.
Management's own commentary supports this outlook. On its latest earnings call, the company described a portfolio undergoing a "meaningful transformation," driven by the "initial launches of over 20 new products, almost all of which have blockbuster potential." This pipeline is what underpins the forecast for expanding profit margins and robust earnings growth. While analysts expect 2026 earnings of about $2.77 per share, management's own guidance for 2026 non-GAAP EPS is higher, in a range of $5.04 to $5.16, suggesting the one-time charges affecting the analyst consensus number are temporary.
And Merck is far from alone: which 10 S&P 500 stocks carry the biggest hidden forward discount? Our rankings sort the entire index by how little you are really paying for each name's growth once the out-year earnings land.
Of course, a stock priced for growth can be volatile. In past market shocks, Merck stock has fallen as much as 62% from its peak. The forward valuation discount offers a cushion, not a guarantee.
Source: Yahoo Finance Top News — This article was automatically imported from the source. Read full article at original source →
